Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension.
CONCLUSIONS: Combination therapy adding a calcium channel blocker, rather than hydrochlorothiazide, to an angiotensin converting enzyme inhibitor was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic blood pressure targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT00170950.
PMID: 33216879 [PubMed - as supplied by publisher] (Source: American...
Source: American Journal of Hypertension - November 20, 2020 Category: Cardiology Authors: Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber MA, Jamerson KA, ACCOMPLISH investigators Tags: Am J Hypertens Source Type: research
A new strategy for taste masking on bitter drug by other combined drug in fixed ‐dose combination: bitterness of Amlodipine besylate could be masked efficiently by Valsartan
ConclusionsIt was suggested that when VAL was mixed with AML, the electrostatic interactions between positive charged amino group of AML and negative charged tetrazole group of VAL were caused, and thereby led the suppression the bitterness of AML. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - July 4, 2019 Category: Drugs & Pharmacology Authors: Honami Kojima,
Saki Nakamura,
Tamami Haraguchi,
Miyako Yoshida,
Masaaki Habara,
Hidekazu Ikezaki,
Takahiro Uchida Tags: Research Paper Source Type: research
Real-World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended-Release Case Study.
This study used metoprolol succinate extended release as a historic case example from which to develop an analytic framework. The US Food and Drug Administration Adverse Event Reporting System was utilized for disproportionality analyses and to identify outcomes of interest. Claims data were analyzed for generic uptake, proportion of prescriptions with "dispense as written" orders, time to discontinuation or switching, and relative rates of clinical events. Adverse Event Reporting System data showed that the Medical Dictionary for Regulatory Activities terms for product quality were higher for generic metoprolol cases and ...
Source: The Journal of Clinical Pharmacology - May 13, 2019 Category: Drugs & Pharmacology Authors: Brown JD, Henriksen C, Vozmediano V, Schmidt S Tags: J Clin Pharmacol Source Type: research
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims
ConclusionsIn this study, we observed that use of generics was associated with comparable clinical outcomes to use of brand-name products. These results could help in promoting educational interventions aimed at increasing patient and provider confidence in the ability of generic medicines to manage chronic diseases. (Source: PLoS Medicine)
Source: PLoS Medicine - March 12, 2019 Category: Internal Medicine Authors: Rishi J. Desai Source Type: research
Systemic arterial hypertension secondary to chronic kidney disease in two captive-born large felids
We describe here the first two cases of spontaneous SHT in large felids, i.e. one 18-year old, 34.4 kg, male North-Chinese leopard (Panthera pardus japonensis, case #1) and one 20-year old, 28.7 kg, female snow leopard (Panthera uncia, case #2), both captive-bred and previously diagnosed with CKD. Both animals underwent complete echocardiographic examination under general anesthesia due to abnormal cardiac auscultation (heart murmur and/or gallop sound), and recurrent lethargy in case #1. The combination of left ventricular remodeling with moderate aortic regurgitation of high velocity was highly suggestive of SHT, whic...
Source: Journal of Veterinary Cardiology - April 21, 2017 Category: Veterinary Research Source Type: research
Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial
Conclusions:
Hypertensive diabetic patients using benazepril had a greater reduction in C-reactive protein, and a slight improvement in FMD, than those taking losartan. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Gismondi, R. A., Oigman, W., Bedirian, R., Pozzobon, C. R., Ladeira, M. C. B., Neves, M. F. Tags: Original Articles Source Type: research
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Conclusions. Increased serum BDNF is associated with reduced eGFR in type 2 diabetic subjects treated with valsartan/hydrochlorothiazide but not with amlodipine/benazepril.
PMID: 25918454 [PubMed - in process] (Source: Disease Markers)
Source: Disease Markers - May 2, 2015 Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial
Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before treatment. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events. We aimed to investigate whether the treatment effects in the ACCOMPLISH trial were dependent on baseline PP. High‐risk hypertensive patients (n=11,499) wer...
Source: The Journal of Clinical Hypertension - December 22, 2014 Category: Cardiology Authors: Per H. Skoglund, Per Svensson, Joline Asp, Björn Dahlöf, Sverre E. Kjeldsen, Kenneth A. Jamerson, Michael A. Weber, Yan Jia, Dion H. Zappe, Jan Östergren, Tags: Original Paper Source Type: research
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study
Conclusions
Azelnidipine is equally effective as a thiazide diuretic in reducing urinary albumin when used in combination with olmesartan. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - July 10, 2013 Category: Transplant Surgery Authors: Kojima, M., Okubo, S., Mizubayashi, R., Isaka, N., Machida, H., Okamoto, S., Hirota, H., Takeuchi, M., Kato, T., Nakatani, K., Mizuno, O., Miyagawa, K., Makino, K., Okura, T., Dohi, Y., Ito, M., Kimura, G. Tags: Chronic Kidney Disease Source Type: research
[Correspondence] Obesity, blood pressure, and cardiovascular outcomes
We read with interest the results of the subanalysis of the ACCOMPLISH trial (Feb 16, p 537), in which the effect of body mass on outcomes differed between the two major therapies tested (benazepril and amlodipine vs benazepril and hydrochlorothiazide). (Source: LANCET)
Source: LANCET - June 7, 2013 Category: Journals (General) Authors: Fernando Elijovich, Cheryl Laffer Tags: Correspondence Source Type: research
Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease
In conclusion, our findings suggest that the combination of B+A should be preferentially used for older patients with high-risk, stage 2 hypertension. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 15, 2013 Category: Cardiology Authors: George Bakris, Alexandros Briasoulis, Bjorn Dahlof, Kenneth Jamerson, Michael A. Weber, Roxzana Y. Kelly, Allen Hester, Tsushung Hua, Dion Zappe, Bertram Pitt, ACCOMPLISH Investigators Tags: Systemic Hypertension Source Type: research
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy.
CONCLUSIONS: The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
PMID: 23512697 [PubMed - as supplied by publisher] (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - March 18, 2013 Category: Cardiology Authors: Hong SH, Wang J, Tang J Tags: Am J Hypertens Source Type: research
Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations
Conclusion:
The results suggested that treatment with FDC AML/OM was associated with greater likelihood of adherence and lower overall costs than with FDC AML/BEN and LDC AML/ARB, and lower risk of cardiovascular event composite versus LDC AML/ARB. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - February 7, 2013 Category: Cardiology Authors: Ferrario, C. M., Panjabi, S., Buzinec, P., Swindle, J. P. Tags: Original Research Source Type: research
